Naphyrone (Molecule of the Month for December 2010)
O-2482, NRG-1, naphthylpyrovalerone,
Naphyrone is a stimulant drug and has been reported as a novel designer drug with effects similar to recently controlled drugs like mephedrone, that acts as a triple reuptake inhibitor. This drug is chemically related to pyrovalerone which used to be prescribed to treat lethargy and fatigue, but was discontinued because of concerns over potential for misuse. Pyrovalerone is already a Class C drug.
The drug has been marketed under the name NRG-1, although only a minority of samples of substances sold under this name have been found to actually contain naphyrone, but instead actually contained a series of recently banned Class B drugs including mephedrone and MDPV. On 7 July 2010, the Advisory Council on the Misuse of Drugs (ACMD) recommended that the government should control naphyrone as a Class B drug under the Misuse of Drug Act, in line with mephedrone and similar stimulant drugs including amphetamine. On 23 July 2010, legislation was passed in parliament that made Naphyrone a Class B drug in line with the ACMD's recommendation. As a result, maximum penalties for possession are 5 years imprisonment plus a fine and for supply are 14 years imprisonment and a fine.
As a triple reuptake inhibitor, naphyrone has been shown in vitro to affect the reuptake of the neurotransmitters serotonin, dopamine and norepinephrine by interacting with the serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). The drug is more toxic than chemically similar drugs like mephedrone.
Formal Chemical Name (IUPAC)
Update by Karl Harrison
(Molecule of the Month for December 2010 )